CUMYL-PEGACLONE (SGT-151) is a
gamma-carboline based
synthetic cannabinoid
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids ( THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synth ...
that has been sold as a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. Des ...
.
The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by
Bristol-Myers Squibb
The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the l ...
in 2001.
Legal status
Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.
See also
*
5F-CUMYL-PEGACLONE
5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB1 receptor. It appears to be ...
*
CUMYL-CB-MEGACLONE
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.
See also
* 5F-CUMYL-PEGACLONE
* CUMYL-5F ...
*
CUMYL-CH-MEGACLONE
CUMYL-CH-MEGACLONE (CUMYL-CHMGACLONE, SGT-270) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in December 2018.
See also
* 5F-CUMYL-PEGACLONE
* CUMYL ...
*
CUMYL-BC-HPMEGACLONE-221
Cumyl-BC-HpMeGaClone-221 (Cumyl-BC .2.1pMeGaClone, SGT-271) is a gamma-carboline derivative which is a synthetic cannabinoid that has been sold as a designer drug. It was first identified in Germany in September 2020.
See also
* CUMYL-CB-MEG ...
*
CUMYL-PINACA
CUMYL-PINACA (also known as SGT-24) is an indazole-3-carboxamide based synthetic cannabinoid. CUMYL-PINACA acts as a potent agonist for the cannabinoid receptors, with approximately 3x selectivity for CB1, having an EC50 of 0.15nM for human CB1 ...
*
CUMYL-5F-P7AICA
*
UR-12
MN-25 (UR-12) is a drug invented by Bristol-Myers Squibb, that acts as a reasonably selective agonist of peripheral cannabinoid receptors. It has moderate affinity for CB2 receptors with a ''K''i of 11 nM, but 22x lower affinity for the ...
References
Cannabinoids
Designer drugs
Gamma-Carbolines
{{cannabinoid-stub